BIOXYTRAN, INC (BIXT)

AI-Powered SEC Filing Analysis

Annual Report Filed: 2026-04-15

Key Insights

The company has accumulated significant losses over the past few years, with a retained earnings deficit of $9.3 million as of 2025-12-31, indicating financial distress.
BIXT has several related party transactions, including a stock purchase agreement and convertible notes with affiliated entities, which raises concerns about potential conflicts of interest.
The company has undertaken a number of private placements of common stock and warrants in 2025, which could lead to dilution for existing shareholders.

Current Report Filed: 2026-03-20

Key Insights

Bioxytran, Inc. has completed a $1.2 million private placement, issuing 21,071,667 shares of common stock at $0.055 per share, along with warrants to purchase 19,750,001 additional shares at $0.12 per share.
The proceeds from the financing will be used for working capital and general corporate purposes, which could support the company's ongoing operations and development efforts.
The private placement was completed with accredited investors, suggesting potential investor interest and confidence in the company's future prospects.

Current Report Filed: 2026-03-02

Key Insights

Bioxytran, Inc. reported positive results from a Phase 1b/2a clinical study of its broad-range antiviral drug ProLectin-M for the treatment of mild to moderate COVID-19 cases.
The successful trial results suggest ProLectin-M could be a promising treatment option for COVID-19 patients, potentially expanding Bioxytran's pipeline and market opportunities.
Investors should closely monitor the company's further development and regulatory progress with ProLectin-M, as positive outcomes could drive future stock performance.

Current Report Filed: 2026-02-17

Key Insights

Bioxytran has entered into a commercial distribution agreement with Khoury Medical LTD to commercialize its proprietary A-SUQAR® dietary supplement, which is intended to support healthy post-meal blood sugar levels.
The agreement represents a new commercialization channel for Bioxytran's product portfolio and could drive revenue growth if the product is successfully launched and adopted by consumers.
The press release indicates that the product is being marketed as a dietary supplement, which suggests it may face less regulatory scrutiny than a pharmaceutical product, potentially streamlining the commercialization process.

Current Report Filed: 2026-02-11

Key Insights

Bioxytran, Inc. reported positive Phase 2 clinical trial results for its ProLectin-M drug candidate, demonstrating rapid viral clearance.
The company's lead drug candidate, ProLectin-M, appears to be effective in treating viral infections, which could be a significant development for the company.
The filing indicates that Bioxytran, Inc. is an emerging growth company, which may provide certain regulatory and financial reporting advantages.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.